Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients Read More Jun 30, 2020
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer Read More Jun 26, 2020
NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis Read More Jun 9, 2020
Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA Read More Apr 8, 2020
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study Read More Mar 31, 2020